Biopharmaceuticals: can India have its cake and eat it?
In late 2011, India adopted a National Manufacturing Policy to boost gross domestic product from 16 percent to 25 percent by 2022. The policy aims to aggressively increase domestic manufacturing capacity, especially in high technology areas.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.